Tuberc Respir Dis.  2009 Aug;67(2):121-126.

Efficacy and Safety of Pemetrexed in Advanced Non-Small Cell Lung Carcinoma

• Lee GJ
• Jung MH
• Jang TW
• Ok CH
• Jung HJ

Abstract

BACKGROUND
Pemetrexed has been prescribed newly as a second line chemotherapy in advanced non-small cell lung carcinoma (NSCLC). The aim of study was to determine the efficacy and toxicity of pemetrexed in advanced NSCLC. METHODS: Patients with histologically or cytologically confirmed NSCLC were evaluated from June 2006 to December 2008. The patients had relapsed or progressed after prior chemotherapy treatment. They were treated with intravenous pemetrexed 500 mg/m2 for 10 min on Day 1 of each 21-day cycle. RESULTS: A total of 89 patients were eligible for analysis. The response rate and disease control rate were 11% and 66%. Non-squamous cell carcinoma histology was significantly associated with a superior response rate (p=0.035) and disease control rate (p=0.009) than squamous cell carcinoma histology. The median survival time was 13 months and the median progression free survival time was 2.3 months. The median survival time of patients with ECOG PS 0~1 was 13.2 months, whereas median survival time was 11.6 months for patients with PS 2 (p=0.002). The median progression free survival time of patients with PS 0~1 were 3.8 months, but 2.1 months for patients with PS 2 (p=0.016). The median progression free survival time of smokers with non-squamous cell carcinoma was 3.4 months, which was significant (p=0.014). Grade 3~4 neutropenia were seen in 7.9% patients. CONCLUSION: Pemetrexed has efficacy in patients who had prior chemotherapy with advanced NSCLC and less hematologic toxicity.

Keyword

Pemetrexed; Non-small-cell lung carcinoma; Drug therapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Disease-Free Survival
Glutamates
Guanine
Humans
Lung
Neutropenia
Pemetrexed
Glutamates
Guanine

Figure

• 

  Figure 1 Waterfall plot of response on pemetrexed in advanced NSCLC. Waterfall plot illustrates patients' response to pemetrexed. Bars represent measurement for Response Evaluation Criteria for Solid Tumor-designated target lesions. Bars below the dotted line represent patients with confirmed partial response.

• 

  Figure 2 Median survival and median progression free survival (PFS) curve of patients with pemetrexed chemotherapy. The median survival time was 13 months and the median progression free survival time was 2.3 months.

• 

  Figure 3 Progression free survival (PFS) curve of patients divided according to smoking and histology subtype. The median progression free survival time of smokers with non-squamous cell carcinoma was 3.4 months, which was significant.

Reference

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008. 58:71–96.

2. Korea National Statistical Office. Annual report on the cause of death statistics, 2007. 2008. Daejeon: Korea National Statistical Office.

3. Herbst RS, Heymach JV, Lippman SM. Lung Cancer. N Engl J Med. 2008. 359:1367–1380.

4. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003. 123:226S–243S.

5. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002. 20:1335–1343.

6. Thödtmann R, Depenbrock H, Dumez H, Blatter J, Johnson RD, van Oosterom A, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol. 1999. 17:3009–3016.

7. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol. 2000. 11:435–440.

8. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. 2001. 92:595–600.

9. Goedhals L, van Wiyk AL, Smith BL, Fourie SJ. Pemetrexed (Alimta LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer. 2006. 16:1172–1178.

10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000. 92:205–216.

11. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001. 19:1734–1742.

12. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000. 18:2095–2103.

13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005. 353:123–132.

14. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004. 22:1589–1597.

15. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist. 2008. 13:Suppl 1. 28–36.

16. Bearz A, Garassino I, Cavina R, Favaretto A, Boccalon M, Talamini R, et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer. 2008. 60:240–245.

17. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007. 18:453–460.

18. Lee HY, Ahn MJ, Park YH, Ahn JS, Kim BS, Kim HK, et al. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. Lung Cancer. Forthcoming 2009.

19. Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol. 2009. 39:27–32.